GO 4
Alternative Names: GO-4Latest Information Update: 27 Oct 2025
At a glance
- Originator General Oncology
- Class Antineoplastics; Aromatic amino acids; Corrinoids; Furans; Myeloablative agonists; Nitrogen mustard compounds; Nitrosourea compounds; Small molecules; Sugar acids; Vitamin B12 analogues; Vitamins
- Mechanism of Action Alkylating agents; DNA damage stimulants; DNA synthesis inhibitors; Immunosuppressants; Nitric oxide inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 18 Oct 2025 Adverse events and efficacy data from a phase I SHARON trial in Cancer (Metastatic disease) released by General Oncology
- 08 Apr 2025 General Oncology has patent protection for GO 4 for the treatment of cancer, prior to April 2025 (General Oncology website, April 2025)
- 08 Apr 2025 General Oncology plans an End-of-Phase I FDA meeting in Q3 2025 (General Oncology pipeline, April 2025)